Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasms 2Smoking 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hyperlipoproteinemia Type II 1Hematologic Neoplasms 1Hearing Loss 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 11Cisplatin 11Carboplatin 7Radiotherapy 6Cetuximab 6Docetaxel 5Surveys and Questionnaires 3Radiotherapy, Intensity-Modulated 3Paclitaxel 3Nivolumab 3Cyclophosphamide 3fludarabine 2cemiplimab 2atezolizumab 2aldesleukin 2Surgical Procedures, Operative 2Standard of Care 2Radiation 2Magnetic Resonance Spectroscopy 2Fluorouracil 2Drug Therapy 2vistusertib 1toripalimab 1sitravatinib 1palbociclib 1osimertinib 1olaparib 1niraparib 1lenvatinib 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × Atorvastatin × 90 days × Clear all
NCT04915183 2026-06-03

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
224 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡